Phase of Development: HTS / Hit ID

Mechanism of Action: Tau Proteostasis, Propagation and Clearance

Compound Type/Modality: Small Molecule

Advancing a Human Stem Cell-Based Platform to Support Discovery of Tauopathy Therapeutics

Stephen Haggarty, PhD

Associate Professor, Department of Neurology, Harvard Medical School Director, Chemical Neurobiology Laboratory, Center for Genomic Medicine Associate Neuroscientist, Massachusetts General Hospital Senior Associate Member, Broad Institute of MIT & Harvard Affiliate Faculty, Harvard Stem Cell Institute

For further information about this program Contact: